99mTc-tetrofosmin SPECT for prediction of functional recovery defined by MRI in patients with severe left ventricular dysfunction: Additional value of gated SPECT

Journal of Nuclear Medicine

Volumn 40, Issue 11, 1999, Pages 1824-1831

  Stollfuss, Jens C ^b   Haas, Felix ^b   Matsunari, Ichiro ^b   Neverve, Jodi ^b   Nekolla, Stephan ^b   Ziegler, Sybille ^b   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

99mTc tetrofosmin; Gated MRI; Gated SPECT; Left ventricular function

Indexed keywords

TETROFOSMIN TC 99M; DIAGNOSTIC AGENT; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

ACCURACY; ADULT; AGED; ARTICLE; BYPASS SURGERY; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; FEMALE; FUNCTIONAL ASSESSMENT; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE PERFUSION; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; HEART; HEART LEFT VENTRICLE FUNCTION; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; ROC CURVE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

CORONARY ARTERY BYPASS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032589707     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Gould KL. Myocardial viability: what does it mean and how to measure it? Circulation. 1991;83:333-335.
2. Baer FM, Voth E, Deutsch HJ, et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol. 1996;28:60-69.
3. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction as evidence for "hibernating myocardium." J Am Coll Cardiol. 1986;8:1467-1470.
4. Brunken R, Tillisch J, Schwaiger M, et al. Regional perfusion, glucose metabolism and wall motion in patients with chronic electrocardiographic Q-wave infarction: evidence for persistence of viable tissue in some infarct regions by positron emission tomography. Circulation. 1986;73:951-961.
5. Tamaki N, Yonekura Y, Yamashita K, et al. Relation of left ventricular perfusion and wall motion with metabolic activity in persistent defects on thallium-201 tomography in healed myocardial infarction. Am J Cardiol. 1988;62:202-208.
6. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884-888.
7. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993;34:30-38.
8. 201TI imaging and coronary angiography in a phase III multicenter trial - Tetrofosmin International Trial Study Group. Circulation. 1995;91:313-319.
9. Tamaki N, Takahashi N, Kawamoto M, et al. Myocardial tomography using technetium-99m-tetrofosmin to evaluate coronary artery disease. J Nucl Med. 1994;35:594-600.
10. Matsunari I, Fujino S, Taki J, et al. Comparison of defect size between thallium-201 and technetium-99m tetrofosmin myocardial single-photon emission computed tomography in patients with single-vessel coronary artery disease. Am J Cardiol. 1996;77:350-354.
11. Beanlands R, Dawood F, Wen W, et al. Are the kinetics of technetium 99m-methoxyisobutyl isonitrile affected by cell metabolism and viability? Circulation. 1990;82:289-296.
12. Matsunari I, Fujino S, Taki J, et al. Myocardial viability assessment with technetium-99m-tetrofosmin and thallium-201 reinjection in coronary artery disease. J Nucl Med. 1995;36:1961-1967.
13. Matsunari I, Fujino S, Taki S, et al. Quantitative rest technetium-99m tetrofosmin imaging in predicting functional recovery after revascularization: comparison with rest-redistribution thallium-201. J Am Coll Cardiol. 1997;29:1226-1233.
14. 201Tl in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation. 1992;86:1125-1137.
15. Pattynama PM, Lamb HJ, Van der Velde EA, Van der Geest RJ, Van der Wall EE, De Roos A. Reproducibility of MRI-derived measurements of right ventricular volumes and myocardial mass. Magn Reson Imaging. 1995;13:53-63.
16. Holman ER, Buller VG, De Roos A, et al. Detection and quantification of dysfunctional myocardium by magnetic resonance imaging: a new three-dimensional method for quantitative wall thickening analysis. Circulation. 1997;95:924-931.
17. DePuey GE, Nichols K, Dobrinsky C. Left ventricular ejection fraction assessed from gated technetium-99m-sestamibi SPECT. J Nucl Med. 1993;34:1871-1876.
18. Okada RD, Murphy JH, Boucher CA, et al. Relationship between septal perfusion, viability and motion before and after coronary artery bypass surgery. Am Heart J. 1992;124:1190-1195.
19. Vignola P, Boucher C, Curfman G. Abnormal interventricular septal motion following cardiac surgery: clinical, surgical, echocardiographic and radionuclide correlates. Am Heart J. 1979;97:27-34.
20. Nekolla SG, Miethaner C, Nguyen N, Ziegler SI, Schwaiger M. Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography. Eur J Nucl Med. 1998;25:1313-1321.
21. Metz CE, Wang P-L, Kronman HB. A new approach for testing the significance of differences between ROC curves measured from correlated data. In: Deconinck F, ed. Information Processing in Medical Imaging. The Hague, The Netherlands: Martinus Nijhoff; 1984:432-445.
22. 99mTc-MIBI emission tomography and by magnetic resonance imaging. Eur J Nucl Med. 1996;23:909-916.
23. Gunning MG, Anagnostolpoulos C, Davies G, Forbat SA, Ell PJ, Underwood R. Gated technetium-99m-tetrofostnin SPECT and cine MRI to assess left ventricular contraction. J Nucl Med. 1997;38:438-442.
24. Stollfuss J, Haas F, Matsunari I, et al. Regional myocardial wall thickening and global ejection fraction in patients with low angiographic ejection fraction assessed by visual and quantitative resting ECG-gated Tc-99m-tetrofosmin single-photon-emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1997;25:522-530.
25. Metz C. Basic principles of ROC analysis. Semin Nucl Med. 1978;8:283-298.
26. Ragosta M, Beller GA, Watson DD, Kaul S, Gimple LW. Quantitative planar rest-redistribution TI-201 imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation. 1993;87:1630-1641.
27. Chua T, Kiat H, Germano G, et al. Gated technetium-99m sestamibi for simultaneous assessment of stress myocardial perfusion, postexercise regional ventricular function and myocardial viability: correlation with echocardiography and rest thallium-201 scintigraphy. J Am Coll Cardiol. 1994;23:1107-1114.
28. Boening G, Ziegler S, Ficaro EP, Schwaiger M. Attenuation correction of gated SPECT: influence of length of transmission scan [abstract]. J Nucl Med. 1997;38(suppl):64P.
29. Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med. 1992;19:874-879.